Research Into Neuroprotection Must Continue … but With a Different Approach

Abstract

HomeStrokeVol. 39, No. 2Research Into Neuroprotection Must Continue … but With a Different Approach Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBResearch Into Neuroprotection Must Continue … but With a Different Approach Muhammad S. Hussain, MD and Ashfaq Shuaib, MD Muhammad S. HussainMuhammad S. Hussain From the Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada. Search for more papers by this author and Ashfaq ShuaibAshfaq Shuaib From the Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada. Search for more papers by this author Originally published17 Jan 2008https://doi.org/10.1161/STROKEAHA.107.494781Stroke. 2008;39:521–522Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 17, 2008: Previous Version 1 Neuroprotective agents disrupting the ischemic cascade and salvaging the ischemic penumbra are being explored as a potential therapeutic option for stroke. Although a number of agents are neuroprotective in animal studies, none of the human trials have been positive, with the exception of the SAINT I trial.1 Unfortunately, the follow-up SAINT II trial had a negative result,2 and a great deal of pessimism regarding the future of neuroprotection has been generated. However, before abandoning neuroprotection as a strategy, it is important to examine where research in neuroprotection has brought us and how we can better design future animal and clinical studies.Lessons LearnedThe main reason for failure has been poor translation from animal studies to clinical trials. Clinical trials often had prolonged therapeutic windows, small sample sizes, and failed to achieve adequate plasma levels of study medications. These problems lead to the Stroke Therapy Academic Industry Roundtable (STAIR) recommendations,3,4 which have greatly improved the methodology of stroke trials. Preclinical development is more rigorous, and clinical trials are attempting to replicate the laboratory, with shorter therapeutic windows and by standardizing stroke severity.The Future of NeuroprotectionOur understanding of the ischemic cascade needs to be further refined, especially in the complex setting of human ischemic stroke. Specific pathways need better characterization, particularly taking into account how factors such as age or comorbidities may influence the cascade. The targets of many of the neuroprotective medications are often speculative, and more effort is needed to determine their precise mechanisms of action. We also should analyze how reducing activity in one of the pathways may influence other pathways within the cascade.Although translational research has improved, current recommendations should be reexamined. NXY-059 met most of the STAIR criteria, but concerns remained, including its ability to cross the blood-brain barrier.5 Investing more time and resources into the animal phase of drug development will be valuable in the long run. This will involve studying animals which more closely mimic human ischemic stroke, such as aged primates with comorbidities like diabetes and hypertension.In translating animal research to clinical trials, another major difficulty has been using consistent outcome measures. In clinical trials, not only is there a change in species, but whereas animal studies use infarct volume as the outcome measure, clinical trials focus on functional outcomes. As an intermediate step, to more closely replicate the animal situation in which the agent shows effectiveness, we should study smaller groups of patients for changes in infarct volume, based on MRI. In these intermediate studies, we can also select patients with a large volume of ischemic penumbra, as to maximize the potential benefit. To do this, better identification of the ischemic penumbra is needed and is a research priority. Diffusion-perfusion mismatch on MRI can provide a rough estimate of penumbral volume and may be a currently usable surrogate marker while other more accurate techniques are found.6 If these smaller intermediate trials are positive, we can then proceed onto larger trials, which allows for better utilization of resources.Our expectation for the role of neuroprotection needs to be reassessed. Decreased cerebral blood flow is the primary initiating event causing cerebral damage, and unless increased perfusion of the ischemic penumbra occurs, the multiple pathways of the ischemic cascade will eventually prevail. Also, without adequate perfusion, it is difficult to achieve sufficient concentrations of neuroprotective medications in the penumbral tissue. Supporting this is the observation that many of the neuroprotective agents are more efficacious in transient occlusion models of stroke.7 Neuroprotective agents may slow down the ischemic cascade, allowing valuable time for reperfusion strategies to be initiated. Thus, neuroprotective therapies should be thought of more as an adjunct to reperfusion, producing either increased efficacy, prolonging time windows, or increased safety of these agents. To effectively stall the ischemic cascade, these therapies have to be initiated quickly. The FAST-MAG protocol is a exciting concept where the magnesium loading dose and infusion are being initiated in the ambulance within minutes to hours after onset of symptoms.8 Also, neuroprotective agents usually target only single or limited aspects of the ischemic cascade. The ischemic cascade has multiple pathways by which it can lead to damage, and it is unlikely that targeting a single aspect of the cascade will be efficacious. One strategy to overcome this may be to target several pathways simultaneously by combining multiple neuroprotective agents acting on different points, thereby halting the majority of the ischemic cascade and resultant damage.Thus, we should reflect on the history of neuroprotection research and acknowledge that, although the breakthrough we are seeking has not been achieved, steady advancement, particularly regarding the methodology of conducting translational research, has occurred. Further refinement and new approaches are now needed, and we must be patient to discover innovative ways to improve outcomes in this debilitating condition.Sources of FundingA. Shuaib has received funds from AstraZeneca, Pfizer, Sanofi, BI, Merck, Roche and Sevier as honorarium and for his research.DisclosuresNone.FootnotesCorrespondence to Dr A. Shuaib, 2E3.13 W.C. Mackenzie Health Sciences Center, University of Alberta, Edmonton, Alberta, Canada, T6G 2B7. E-mail [email protected] References 1 Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. Nxy-059 for acute ischemic stroke. N Engl J Med. 2006; 354: 588–600.CrossrefMedlineGoogle Scholar2 Shuaib A LK, Grotta J, Lyden P, Davalos A, Davis SM, Diener HC, Wasiewski W, Wilmington DE, Ashwood T, Hardemark HG, Emeribe U for the SAINT investigators. Saint ll: Results of the second randomized, multicenter, placebo-controlled, double-blind study of nxy-09 treatment in patients with acute ischemic stroke. International Stroke Conference. 2007.Google Scholar3 Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999; 30: 2752–2758.CrossrefMedlineGoogle Scholar4 Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001; 32: 1598–1606.CrossrefMedlineGoogle Scholar5 Fisher M, Lees K, Papadakis M, Buchan AM. Nxy-059: Brain or vessel protection. Stroke. 2006; 37: 2189–2190.LinkGoogle Scholar6 Kidwell CS, Alger JR, Saver JL. Beyond mismatch: Evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke. 2003; 34: 2729–2735.LinkGoogle Scholar7 Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2002; 33: 306–307.LinkGoogle Scholar8 Saver JL, Kidwell C, Eckstein M, Ovbiagele B, Starkman S. Physician-investigator phone elicitation of consent in the field: A novel method to obtain explicit informed consent for prehospital clinical research. Prehosp Emerg Care. 2006; 10: 182–185.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Pound P and Ram R (2020) Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers, BMJ Open Science, 10.1136/bmjos-2019-100041, 4:1, (e100041), Online publication date: 1-Jan-2020. Sun B, He M, Han X, Sun J, Yang M, Yuan H, Fan C, Zhang S, Mao L, Li D, Zhang Z, Zheng C, Yang X, Li Y, Stetler R, Chen J and Zhang F (2014) Intranasal Delivery of Granulocyte Colony-Stimulating Factor Enhances Its Neuroprotective Effects Against Ischemic Brain Injury in Rats, Molecular Neurobiology, 10.1007/s12035-014-8984-2, 53:1, (320-330), Online publication date: 1-Jan-2016. Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, Esposito E and Cuzzocrea S (2015) Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man, Translational Stroke Research, 10.1007/s12975-015-0440-8, 7:1, (54-69), Online publication date: 1-Feb-2016. Stokum J, Gerzanich V and Simard J (2015) Molecular pathophysiology of cerebral edema, Journal of Cerebral Blood Flow & Metabolism, 10.1177/0271678X15617172, 36:3, (513-538), Online publication date: 1-Mar-2016. Wang X, Luo Y, Sun H, Feng J, Ma S, Liu J and Huang B (2014) Dynamic expression changes of Bcl-2, Caspase-3 and Hsp70 in middle cerebral artery occlusion rats, Brain Injury, 10.3109/02699052.2014.945958, 29:1, (93-97), Online publication date: 2-Jan-2015. Fedin A, Vasilenko I and Badalyan K (2015) The effect of cholesterol on the electrokinetic properties of erythrocyte membranes in chronic cerebral ischemia, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 10.17116/jnevro20151159230-37, 115:9. Vyp. 2, (30), . Xu S and Pan S (2013) Clinical translational failure in neuroprotective agents: the steps from animal experiments to clinical trials, Medical Science Monitor Basic Research, 10.12659/MSMBR.883750, 19, (37-45) Sucher N and Carles M (2013) Chinese Herbal Medicines for Neuroprotection in Ischemic Stroke: Promise and Reality Evidence and Rational Based Research on Chinese Drugs, 10.1007/978-3-7091-0442-2_9, (363-395), . Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, Esposito E and Cuzzocrea S (2012) Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats, Brain Research, 10.1016/j.brainres.2012.08.006, 1477, (45-58), Online publication date: 1-Oct-2012. Garg P, Duncan R, Kaja S, Zabaneh A, Chapman K and Koulen P (2011) Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke, Neuroscience Letters, 10.1016/j.neulet.2011.01.073, 492:3, (134-138), Online publication date: 1-Apr-2011. Huang L, Chen N, Ge M, Zhu Y, Guan S and Wang J (2010) Ca2+ and acidosis synergistically lead to the dysfunction of cortical GABAergic neurons during ischemia, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2010.03.056, 394:3, (709-714), Online publication date: 1-Apr-2010. Nategh M, Shaveisi K, Shabanzadeh A, Sadr S, Parviz M and Ghabaei M (2010) Systemic Hyperthermia Masks the Neuroprotective Effects of MK-801, but not Rosiglitazone in Brain Ischaemia, Basic & Clinical Pharmacology & Toxicology, 10.1111/j.1742-7843.2010.00570.x, 107:3, (724-729), Online publication date: 1-Sep-2010. Susser E and Ritsner M (2010) Brain Protection in Neuropsychiatric Disorders: Past, Present and Future Challenges Brain Protection in Schizophrenia, Mood and Cognitive Disorders, 10.1007/978-90-481-8553-5_1, (3-25), . Johnson S and Turner S (2010) Protecting motor networks during perinatal ischemia: the case for delta-opioid receptors, Annals of the New York Academy of Sciences, 10.1111/j.1749-6632.2010.05434.x, 1198:1, (260-270), Online publication date: 1-Jun-2010. Apolloni S, Montilli C, Finocchi P and Amadio S (2008) Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events, FEBS Journal, 10.1111/j.1742-4658.2008.06796.x, 276:2, (354-364), Online publication date: 1-Jan-2009. Liu S and Levine S (2008) The Continued Promise of Neuroprotection for Acute Stroke Treatment, Journal of Experimental Stroke and Translational Medicine, 10.6030/1939-067X-1.1.1, 1:1, (1-8), Online publication date: 1-Jan-2008. Fusco R, Scuto M, Cordaro M, D’Amico R, Gugliandolo E, Siracusa R, Peritore A, Crupi R, Impellizzeri D, Cuzzocrea S and Di Paola R (2019) N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway, International Journal of Molecular Sciences, 10.3390/ijms20194845, 20:19, (4845) February 2008Vol 39, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/STROKEAHA.107.494781PMID: 18202310 Manuscript receivedMay 28, 2007Manuscript acceptedMay 30, 2007Originally publishedJanuary 17, 2008 KeywordsneuroprotectantsneuroprotectionPDF download Advertisement